Jump to content

User:Lshvosatka/sandbox/chem275

From Wikipedia, the free encyclopedia
Maitansine
Names
IUPAC name
N-Acetyl-N-methyl-L-alanine(1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*))-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethy-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo(19.3.1.1(sup 10,14).0(sup 3,5))hexacosa-10,12,14(26),16,18-pentaen-6-yl ester
Other names
Maytansin
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
UNII
  • InChI=1S/C34H46ClN3O10/c1-18-11-10-12-26(45-9)34(43)17-25(46-32(42)36-34)19(2)30-33(5,48-30)27(47-31(41)20(3)37(6)21(4)39)16-28(40)38(7)23-14-22(13-18)15-24(44-8)29(23)35/h10-12,14-15,19-20,25-27,30,43H,13,16-17H2,1-9H3,(H,36,42)/b12-10+,18-11+/t19-,20+,25+,26-,27+,30+,33+,34+/m1/s1
    Key: WKPWGQKGSOKKOO-RSFHAFMBSA-N
  • C/C(CC1=CC(OC)=C(Cl)C(N3C)=C1)=C\C=C\[C@@H](OC)[C@@]2(O)C[C@]([C@@H](C)[C@H]4[C@](O4)(C)[C@@H](OC([C@H](C)N(C)C(C)=O)=O)CC3=O)([H])OC(N2)=O
Properties
C34H46ClN3O10
Molar mass 692.20 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Tracking categories (test):

Maitansine (INN), or maytansine (USAN), is a cytotoxic agent. It inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site,[1] with a KD of approximately 1 μmol/L.[2] This property made Maitansine a potential anti-cancer drug, with an IC50 of 1.6 x 10-11 M in vivo, approximately 100 to 1000 times more toxic than other anti-cancer drugs.[3] This high toxicity and its lack of specificity resulted in unsuccessful clinical trials.[2]

It is an antibiotic macrolide of the ansamycin type and can be isolated from plants of the genus Maytenus.[1] It is believed to first have been isolated from either Maytenus serrata or Maytenus ovatus.[4][2]

Maytansinoids

[edit]
Each maytansinoid has this basic structure with a different R-group (highlighted in red).

Derivatives of maitansine are known as maytansinoids formed by changing the R-group[5], shown in red in the above image, to increase target specificity.[2][6] Target specificity is improved by conjugating the maitansinoids to antibodies.[2]

These derivatives also do not inhibit microtubule assembly as well as Maytansine, but have been seen to suppress dynamic instability, the stochastic switches between growing and shortening, more strongly.[2] Some are being investigated as the cytotoxic component of antibody-drug conjugates for cancer treatment,[3] and the antibody-drug conjugate trastuzumab emtansine is an approved drug for the treatment of certain kinds of breast cancer in the EU and in the US.[6][7]

Examples of maytansinoids are:

See also

[edit]
  • ImmunoGen, developer of maytansinoid based drugs

References

[edit]
  1. ^ a b National Cancer Institute: Definition of Maytansine
  2. ^ a b c d e f Lopus, M; Oroudjev, E; Wilson, L; Wilhelm, S; Widdison, W; Chari, R; Jordan, MA (2010). "Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules". Mol Cancer Ther. 9 (10): 2689–99. doi:10.1158/1535-7163.MCT-10-0644. PMC 2954514. PMID 20937594.
  3. ^ a b Chari, RV; Martell, BA; Gross, JL; et al. (January 1992). "Immunoconjugates containing novel maytansinoids: promising anticancer drugs" (PDF). Cancer Res. 52 (1): 127–31. PMID 1727373.
  4. ^ "NCI Thesaurus". ncithesaurus.nci.nih.gov. Retrieved 2023-04-27.
  5. ^ a b Yu, T.-W.; Bai, L; Clade, D; Hoffmann, D; Toelzer, S; Trinh, KQ; Xu, J; Moss, SJ; Leistner, E (2002). "The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnemapretiosum". Proceedings of the National Academy of Sciences. 99 (12): 7968–7973. Bibcode:2002PNAS...99.7968Y. doi:10.1073/pnas.092697199. PMC 123004. PMID 12060743.
  6. ^ a b "Kadcyla EPAR". European Medicines Agency (EMA). 17 September 2018.
  7. ^ "Drug Approval Package: ado-trastuzumab emtansine". U.S. Food and Drug Administration (FDA). 22 February 2013. Archived from the original on 4 December 2019. Retrieved 3 December 2019.